S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.54 (-2.30%)
AMD   100.08 (-3.09%)
T   14.78 (+0.75%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-7.30%)
GE   107.76 (-0.95%)
DIS   79.54 (-2.61%)
AMC   7.85 (-3.68%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:KTRA

Kintara Therapeutics (KTRA) Stock Forecast, Price & News

$3.87
-0.01 (-0.26%)
(As of 01:29 PM ET)
Compare
Today's Range
$3.87
▼
$4.21
50-Day Range
$3.30
▼
$4.92
52-Week Range
$2.70
▼
$15.50
Volume
3,800 shs
Average Volume
76,143 shs
Market Capitalization
$6.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Kintara Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Kintara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to $0.05 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

See Top Rated MarketRank™ Stocks Here

KTRA stock logo

About Kintara Therapeutics (NASDAQ:KTRA) Stock

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA Price History

KTRA Stock News Headlines

October 2, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
September 25, 2023 | finance.yahoo.com
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
October 3, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
September 19, 2023 | seekingalpha.com
Kintara Therapeutics Non-GAAP EPS of -$9.27
September 18, 2023 | finance.yahoo.com
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
September 14, 2023 | uk.finance.yahoo.com
KTRA - Kintara Therapeutics, Inc.
September 5, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
August 17, 2023 | finance.yahoo.com
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
October 3, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
August 9, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the Emerging Growth Conference
August 8, 2023 | finance.yahoo.com
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
July 14, 2023 | msn.com
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
June 30, 2023 | finance.yahoo.com
Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy
June 29, 2023 | benzinga.com
Kintara Therapeutics Stock Is Trading Higher: What's Driving The Action?
June 28, 2023 | finance.yahoo.com
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001
June 16, 2023 | finance.yahoo.com
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
May 19, 2023 | finance.yahoo.com
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society
May 12, 2023 | msn.com
Recap: Kintara Therapeutics Q3 Earnings
May 11, 2023 | finance.yahoo.com
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update
May 8, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
May 1, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the Aegis Capital Virtual Conference
April 14, 2023 | finance.yahoo.com
Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting
March 17, 2023 | ca.finance.yahoo.com
These 4 Biotech Stocks Just Got ‘Fast Track’ Designation Greenlights
March 15, 2023 | finance.yahoo.com
Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
March 10, 2023 | finance.yahoo.com
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
February 14, 2023 | finance.yahoo.com
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
January 30, 2023 | finance.yahoo.com
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
See More Headlines
Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTRA Company Calendar

Last Earnings
11/15/2021
Today
10/03/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTRA
CUSIP
N/A
CIK
1498382
Web
www.kintara.com
Phone
(858) 350-4364
Fax
604-608-5685
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($9.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,650,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-173.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.06
Quick Ratio
1.06

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.86) per share
Price / Book
-0.68

Miscellaneous

Outstanding Shares
1,750,000
Free Float
1,662,000
Market Cap
$6.95 million
Optionable
Not Optionable
Beta
1.04
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert E. Hoffman B.B.A. (Age 57)
    CPA, CPA, Pres, CEO, Interim CFO & Chairman
    Comp: $768.29k
  • Dr. Dennis M. Brown B.Sc. (Age 73)
    M.A., Ph.D., Co-Founder & Chief Scientific Officer
    Comp: $247.28k
  • Mr. Jeffrey A. Bacha B.Sc. (Age 55)
    M.B.A., Founder
  • Mr. Greg A. Johnson
    Acting Head of Operations

Key Competitors

View All Competitors













KTRA Stock - Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KTRA shares.
View KTRA analyst ratings or view top-rated stocks.

How have KTRA shares performed in 2023?

Kintara Therapeutics' stock was trading at $6.89 at the beginning of 2023. Since then, KTRA stock has decreased by 42.4% and is now trading at $3.97.
View the best growth stocks for 2023 here.

Are investors shorting Kintara Therapeutics?

Kintara Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 9,600 shares, a decrease of 66.6% from the August 31st total of 28,700 shares. Based on an average daily trading volume, of 158,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.6% of the shares of the stock are short sold.
View Kintara Therapeutics' Short Interest.

When is Kintara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our KTRA earnings forecast.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its quarterly earnings results on Monday, November, 15th. The company reported ($8.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.00) by $1.50.

When did Kintara Therapeutics' stock split?

Shares of Kintara Therapeutics reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

What is Kintara Therapeutics' stock symbol?

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kintara Therapeutics' stock price today?

One share of KTRA stock can currently be purchased for approximately $3.97.

How much money does Kintara Therapeutics make?

Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $6.95 million. The company earns $-14,650,000.00 in net income (profit) each year or ($9.49) on an earnings per share basis.

How can I contact Kintara Therapeutics?

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685.

This page (NASDAQ:KTRA) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -